Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | BMC Cancer

Figure 5

From: Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma

Figure 5

Combination of immatinib with IFN- improved the effect of the re-initiated treatment. The combination treatment of imatinib (100 mg/kg/day) and re-initiated IFN-α (1.5 ×10 7 U/kg/day) resulted in decreased phosphorylation of PDGFR, AKT, and ERK compared with IFN treatment alone or control group (A), and decreased tumor weight and MVD (B); Double staining of CD31 (for endothelial cells, green) and α-SMA (for pericyte, red) showed fewer pericytes were found in tumor vessels in combination treatment group compared with IFN-α or normal saline treatment groups (C), scale bar = 20 μm.

Back to article page